VivoSeq
Cardiovascular

Paroxysmal Supraventricular Tachycardia

3

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Paroxysmal supraventricular tachycardia is an early-stage landscape with 3 programs across 4 companies. The most active players are Milestone Pharmaceuticals Inc., Astellas, Val Adams. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Milestone Pharmaceuticals Inc.

1 program

Phase 3Astellas logo

Astellas

1 program

Phase 3V

Val Adams

1 program

Phase 3C

Corxel Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 33

Adenosine

Astellas

Verapamil

Val Adams

Etripamil

Milestone Pharmaceuticals Inc.

Approved
No programs

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Terminated2 · 33%
Recruiting1 · 17%
Enrolling by invitation1 · 17%

Clinical Trials

Trial Activity

6 trials

Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients
Recruiting·RRashid Latif Medical College·Phase 3·NCT06717685·210 enrolled
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Enrolling by invitation·MMilestone Pharmaceuticals Inc.·Phase 3·NCT04952610·130 enrolled
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Completed·MMilestone Pharmaceuticals Inc.·Phase 3·NCT04072835·1,116 enrolled
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Completed·CCorxel Pharmaceuticals·Phase 3·NCT05410860·500 enrolled
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Terminated·MMilestone Pharmaceuticals Inc.·Phase 3·NCT03635996·169 enrolled
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
Terminated·MMilestone Pharmaceuticals Inc.·Phase 3·NCT03464019·1,097 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)